

Regd. Office: 93, Jayprakash Road, Andheri (West), Mumbai - 400 058. Phone: 022-67 603 603 Fax: 91-22-66943127

Statement of Standalone Unaudited Financial Results for the Quarter Ended on 30/06/2017

(Rs. In Lacs except EPS)

Sr. No.		Particulars	Quarter Ended			year ended
			30/06/2017	31/03/2017	30/06/2016	31/03/2017
			Unaudited	Audited	Unaudited	Audited
1		Revenue from Operations	1699.40	2740.05	2230.44	10330.60
2		Other Income	111.10	88.38	73.16	276.42
3		Total income	1810.50	2828.43	2303.60	10607.02
4		Expenses				
	(a)	Cost of Materials Consumed	189.46	254.63	163.11	804.25
	(b)	Purchase of Stock-in-trade	479.30	654.16	380.28	2447.12
	10 11	Changes in inventories of Finished Goods, Stock-in- trade and WIP	-35.25	-174.68	179.21	-195.45
	(d)	Employee benefit expenses	644.60	605.44	616.61	2425.69
	(e)	Finance Costs	8.82	12.62	9.04	41.00
	(f)	Depreciation and Amortisation Expense	36.09	44.82	44.11	178.72
	(g)	other expenses	778.75	831.71	616.44	2874.85
		Total Expenses	2101.77	2228.70	2008.80	8576.18
5		Profit before exceptional items & Tax		599.73		2030.84
6	_	Exceptional Items		0.40		12.79
7		Profit before tax	-291.27	600.13	294.80	2043.63
8		Tax Expense				
	(i)	Current Tax	0.00	250.41	100.00	710.00
	(ii)	Deferred Tax	-3.33	-3.67	0.06	-12.82
9		Profit after tax for the period	-287.94	353.39	194.74	1346.45
10		Other Comprehensive Income	Ü			
		Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	(111)	Income Tax relatiing to Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
11		Total Comprehensive Income for the period	-287.94	353.39	194.74	1346.45
12		Earnings Per Share Basic and Diluted (In Rs.)	-6.19	7.60	4.19	28.96

Notes:

- The Company has adopted Indian Accounting Stanards (IND AS) prescribed under section 133 of the Companies Act 2013 read with the relevant rules issued thereunder, from April 01, 2017. The Company has adopted all required standards under the IND AS and adoption were carried out in accordance with IND AS 101, first time adoption of IND AS. These unaudited financial result including figures for the quarter ended June 30, 2016, have been prepared in accordance with the recognition and measurement principles laid down in IND AS 34 "Interim Financial Reporting" and the other accounting principles generally accepted in India.
- 2 The financial results and other financial information for the quarter ended June 30, 2016 have not been audited by the Statutory Auditors. However, the management has exercised necessary due diligence to ensure that the unaudited financial results provide a true and fair view of the Company's affairs.
- 🌞 Science hai toh Hope hai 🎇 Hope hai toh Health hai 🎆 Health hai toh Happiness hai 🌞

Email: info@jenburkt.com www.jenburkt.com CIN No. L24230MH1985PLC036541

1/2





Regd. Office: 93, Jayprakash Road, Andheri (West), Mumbai - 400 058. Phone: 022-67 603 603 Fax: 91-22-66943127

- 3 The figures of the previous year/period have been regrouped/recast to render them comparable with figures of the current period.
- Reconciliation of net profit for the quarter ended June 30, 2016, previous GAAP and IND AS is as under

Particulars	Profit Reconciliation	
Net Profit for the quarter as per Previous GAAP	194.95	
ADD/(LESS) : Adjustments of difference between figures as per GAAP and IND AS		
Deferment of Revenue Recognition	0.48	
Impact of Deferred Tax	-0.54	
Discounting of Rent Deposit	-0.52	
Others	0.37	
Net Profit for the quarter as per IND AS	194.74	

- 5 The Company is dealing exclusively in Pharmaceuticals business segment, hence segment wise reporting is not applicable.
- 6 After completion of the Board Meeting, the Company could not submit the above unaudited financial results within stipulated time limit, due to power failure caused by the unprecedented heaviest rain in Mumbai. It is submitted on restoration of power.

By Order of the Board For Jenburkt Pharmaceuticals Ltc

Place: Mumbai

Date: 30th August, 2017

(Dilip H. Bhuta)

Whole Time Director & CF(

D.R.MEHTA & ASSOCIATES

(CHARTERED ACCOUNTANTS)

H-2, EVEREST BUILDING, 9TH FLOOR, TARDEO CIRCLE, MUMBAI – 400034. TEL: 23513758 / 23520330, 9322508373

Email ID: info@drmehta.in, vikram@drmehta.in, ashok@drmehta.in

Review Report to The Board of Directors

Jenburkt Pharmaceuticals Ltd.

We have reviewed the accompanying statement of unaudited financial results of Jenburkt Pharmaceuticals Ltd. *(CIN No. **L24230MH1985PLC036541)** for the quarter ended 30th June 2017. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D R Mehta & Associates

Chartered Accountants

(FRN. 106207W)

Signature Ashok Mehta Partner

(M. No.:101746)

ASHOK D. MEHTA M. NO. 101746

Place: Mumbai

Date: 29th August 2017